Prognostic Impact of Main Lymph Node Metastasis in Patients with Colon Cancer

• Published in: World journal of surgery 2023-05, Vol.47 (5), p.1292-1302
• Main Authors: Sugiura, Kiyoaki, Seo, Yuki, Tajima, Yuki, Kikuchi, Hiroto, Hirata, Akira, Nakadai, Jumpei, Baba, Hideo, Kondo, Takayuki, Makino, Akitsugu, Kato, Yujin, Matsui, Shimpei, Seishima, Ryo, Shigeta, Kohei, Okabayashi, Koji, Kitagawa, Yuko
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Cancer; Cardiac Surgery; Colon cancer; Colonic Neoplasms - pathology; Colonic Neoplasms - surgery; Colorectal cancer; Dissection; General Surgery; Health hazards; Humans; Lymph Node Excision; Lymph nodes; Lymph Nodes - pathology; Lymph Nodes - surgery; Lymphatic Metastasis - pathology; Lymphatic system; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Multivariate analysis; Neoplasm Staging; Original Scientific Report; Patients; Prognosis; Rank tests; Retrospective Studies; Surgery; Survival; Survival analysis; Thoracic Surgery; Vascular Surgery
• ISSN: 0364-2313; 1432-2323
• DOI: 10.1007/s00268-023-06918-5

Background Although extended lymph node dissection during colon cancer surgery is recommended in both Western and Eastern countries, the perception and clinical significance of main lymph node metastasis (MLNM) remains controversial. Methods In total, 1557 patients with colon cancer who underwent curative resection with D3 dissection were retrospectively analyzed. Clinicopathological factors associated with MLNM were analyzed. Kaplan–Meier survival analysis and log-rank tests were used to compare the prognosis between the MLNM and non-MLNM groups. Results Multivariate analysis showed that overall survival (OS) [hazard ratio, 2.117 (0.939–4.774), p  = 0.071] and recurrence-free survival (RFS) [hazard ratio, 2.183 (1.182–4.031), p  = 0.013] were affected by the MLNM status independent of the TNM stage. Survival analysis demonstrated that among patients with stage III disease, the OS and RFS rates were significantly different between patients with and without MLNM (OS: p  = 0.0147, RFS: p  = 0.0001). However, the OS and RFS rates were not significantly different between patients who had stage III disease with MLNM and patients who had stage IV disease (OS: p  = 0.5901, RFS: p  = 0.9610). Conclusions MLNM is an independent prognostic factor for patients with colon cancer. The addition of the MLNM status to the current TNM classification may enhance the prognostic value of the TNM staging system and the clinical efficacy of adjuvant therapy in patients with colon cancer.